• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Travere Therapeutics Inc (NQ: TVTX )

    10.19 +0.30 (+3.03%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 29, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,316,418
    Open 9.910
    Bid (Size) 10.01 (1)
    Ask (Size) 10.85 (30)
    Prev. Close 9.890
    Today's Range 9.910 - 10.72
    52wk Range 5.120 - 17.57
    Shares Outstanding 60,717,176
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Week In Review: Nanjing Triastek Partners With BioNTech In A $1.2 Billion Drug Development Deal
    Triastek will develop oral RNA therapeutics with Germany’s BioNTech based on its 3D printing technology. Triastek will receive a $10 million upfront payment and up to $1.2 billion in milestones, plus... 
    Via Talk Markets
    Travere Therapeutics to Report Second Quarter 2024 Financial Results
    From Travere Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    +6.59%
    +6.59%
    1 Month
    +23.07%
    +23.07%
    3 Month
    +86.63%
    +86.63%
    6 Month
    +9.33%
    +9.33%
    1 Year
    -40.72%
    -40.72%

    More News

    Read More
    10 Health Care Stocks Whale Activity In Today's Session
    Via Benzinga
    Nvidia, Micron, Arlo Technologies And Other Big Stocks Moving Higher On Tuesday
    Via Benzinga
    Expert Outlook: Travere Therapeutics Through The Eyes Of 6 Analysts
    Via Benzinga
    Critical Insights From Travere Therapeutics Analyst Ratings: What You Need To Know
    Via Benzinga
    Travere Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference
    From Travere Therapeutics, Inc.
    Via GlobeNewswire
    Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Travere Therapeutics, Inc.
    Via GlobeNewswire
    Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Travere Therapeutics, Inc.
    Via GlobeNewswire
    Peeling Back The Layers: Exploring Travere Therapeutics Through Analyst Insights
    Via Benzinga
    Deep Dive Into Travere Therapeutics Stock: Analyst Perspectives (7 Ratings)
    Via Benzinga
    Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress
    From Travere Therapeutics, Inc.
    Via GlobeNewswire
    Travere Therapeutics to Present at Upcoming Investor Conferences
    From Travere Therapeutics, Inc.
    Via GlobeNewswire
    TVTX Stock Earnings: Travere Therapeutics Misses EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    Travere Therapeutics Reports First Quarter 2024 Financial Results
    From Travere Therapeutics, Inc.
    Via GlobeNewswire
    Earnings Scheduled For February 15, 2024
    Via Benzinga
    Travere Therapeutics to Report First Quarter 2024 Financial Results
    From Travere Therapeutics, Inc.
    Via GlobeNewswire
    Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
    From Travere Therapeutics, Inc.
    Via GlobeNewswire
    Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International
    From Travere Therapeutics, Inc.
    Via GlobeNewswire
    Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association
    From Travere Therapeutics, Inc.
    Via GlobeNewswire
    Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Travere Therapeutics, Inc.
    Via GlobeNewswire
    Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)
    From Travere Therapeutics, Inc.
    Via GlobeNewswire
    Travere Therapeutics to Present at Upcoming Investor Conferences
    From Travere Therapeutics, Inc.
    Via GlobeNewswire
    Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
    From Travere Therapeutics, Inc.
    Via GlobeNewswire
    Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
    From Travere Therapeutics, Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.